Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants

Shujin Wang; Yan Yu; Paul Ryan; Minyan Dang; Cain Clark; Vasileios  Kontogi; Jamal Rahmani; Hamed Kord-Varkaneh; Ammar  Salehisahlabadi; Andrew S Day; Yong Zhang

doi:10.1016/j.phrs.2019.104585

Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants

Shujin Wang, Yan Yu, Paul Ryan, Minyan Dang, Cain Clark, Vasileios Kontogi, Jamal Rahmani, Hamed Kord-Varkaneh, Ammar Salehisahlabadi, Andrew S Day, Yong Zhang

Research output: Contribution to journal › Review article › peer-review

37 Citations (Scopus)

124 Downloads (Pure)

Abstract

Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I2=90%). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models.

Original language	English
Article number	104585
Journal	Pharmacological Research
Volume	151
Early online date	6 Dec 2019
DOIs	https://doi.org/10.1016/j.phrs.2019.104585
Publication status	Published - Jan 2020

Bibliographical note

NOTICE: this is the author’s version of a work that was accepted for publication in Pharmacological Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Pharmacological Research, 151, (2020) DOI: 10.1016/j.phrs.2019.104585

© 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Keywords

Aspirin
Hepatocellular carcinoma
Liver cancer

ASJC Scopus subject areas

Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.phrs.2019.104585

Post-PrintAccepted author manuscript, 341 KBLicence: CC BY-NC-ND

Cite this

Wang, S., Yu, Y., Ryan, P., Dang, M., Clark, C., Kontogi, V., Rahmani, J., Kord-Varkaneh, H., Salehisahlabadi, A., Day, A. S., & Zhang, Y. (2020). Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants. Pharmacological Research, 151, Article 104585. https://doi.org/10.1016/j.phrs.2019.104585

Wang, S, Yu, Y, Ryan, P, Dang, M, Clark, C, Kontogi, V, Rahmani, J, Kord-Varkaneh, H, Salehisahlabadi, A, Day, AS & Zhang, Y 2020, 'Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants', Pharmacological Research, vol. 151, 104585. https://doi.org/10.1016/j.phrs.2019.104585

@article{c1df19f7b3264b4e9257105cf03c40a0,

title = "Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants",

abstract = "Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I2=90%). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models. ",

keywords = "Aspirin, Hepatocellular carcinoma, Liver cancer",

author = "Shujin Wang and Yan Yu and Paul Ryan and Minyan Dang and Cain Clark and Vasileios Kontogi and Jamal Rahmani and Hamed Kord-Varkaneh and Ammar Salehisahlabadi and Day, {Andrew S} and Yong Zhang",

note = "NOTICE: this is the author{\textquoteright}s version of a work that was accepted for publication in Pharmacological Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Pharmacological Research, 151, (2020) DOI: 10.1016/j.phrs.2019.104585 {\textcopyright} 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ ",

year = "2020",

month = jan,

doi = "10.1016/j.phrs.2019.104585",

language = "English",

volume = "151",

journal = "Pharmacological Research",

issn = "1043-6618",

publisher = "Elsevier",

}

TY - JOUR

T1 - Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants

AU - Wang, Shujin

AU - Yu, Yan

AU - Ryan, Paul

AU - Dang, Minyan

AU - Clark, Cain

AU - Kontogi, Vasileios

AU - Rahmani, Jamal

AU - Kord-Varkaneh, Hamed

AU - Salehisahlabadi, Ammar

AU - Day, Andrew S

AU - Zhang, Yong

N1 - NOTICE: this is the author’s version of a work that was accepted for publication in Pharmacological Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Pharmacological Research, 151, (2020) DOI: 10.1016/j.phrs.2019.104585 © 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

PY - 2020/1

Y1 - 2020/1

N2 - Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I2=90%). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models.

AB - Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I2=90%). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models.

KW - Aspirin

KW - Hepatocellular carcinoma

KW - Liver cancer

UR - http://www.scopus.com/inward/record.url?scp=85076294424&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2019.104585

DO - 10.1016/j.phrs.2019.104585

M3 - Review article

SN - 1043-6618

VL - 151

JO - Pharmacological Research

JF - Pharmacological Research

M1 - 104585

ER -

Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this